

2643 '00 MAR -6 A9:18

A Partnership Including  
Professional Corporations  
600 13th Street, N.W.  
Washington, D.C. 20005-3096  
202-756-8000  
Facsimile 202-756-8087  
<http://www.mwe.com>

Boston  
Chicago  
London  
Los Angeles  
Miami  
Moscow  
Newport Beach  
New York  
St. Petersburg  
Silicon Valley  
Vilnius  
Washington, D.C.

David L. Rosen  
Attorney at Law  
[drosen@mwe.com](mailto:drosen@mwe.com)  
202-756-8075

**MCDERMOTT, WILL & EMERY**

March 3, 2000

**VIA FEDERAL EXPRESS**

Dockets Management Branch  
Food and Drug Administration  
Department of Health and Human Services  
5630 Fishers Lane, Room 1061  
Rockville, MD 20852

**ANDA SUITABILITY PETITION**

McDermott, Will & Emery submits this ANDA Suitability Petition under the provisions of section 505 (j)(2)(C) of the Federal Food, Drug and Cosmetic Act requesting that the Commissioner of Food and Drugs allow the submission and filing of an Abbreviated New Drug Application ("ANDA") for Albuterol Sulfate Inhalation Solution, 0.0417% as discussed below.

**A. Action Requested**

The Petitioner requests that the Commissioner of Food and Drugs allow the submission and filing of an ANDA for Albuterol Sulfate Inhalation Solution, 0.0417% per 3mL pursuant to Section 505(j)(2)(C) of the Federal Food, Drug and Cosmetic Act. Specifically, the proposed product is formulated as a pre-diluted, nonpreserved version of Glaxo's product, Ventolin<sup>®</sup>, Albuterol Sulfate Inhalation Solution 0.5%, NDA No. 19-269. Glaxo's Ventolin<sup>®</sup> product (0.25mL) must be diluted with Sterile Normal Saline Solution (2.75mL) which results in a final concentration of 0.0417%, the same concentration as the proposed product. This dosage is intended for pediatric use. Draft labeling is enclosed with this petition.

00P-0913

CPI

**B. Statement of Grounds**

1. FDA has designated two albuterol sulfate inhalation solution, 0.5% reference listed drugs in the publication "Approved Drug Products with Therapeutic Equivalence Evaluations (the "Orange Book") for the purpose of serving as the reference listed drug for generic products:
2. Schering's brand of Albuterol Sulfate Inhalation Solution, 0.5%, Proventil<sup>®</sup>, NDA No. 19-243 which contains the preservative Benzalkonium Chloride; and, Glaxo's Ventolin<sup>®</sup>, NDA No. 19-269 which contains no preservatives.
3. As noted in the Orange Book, both of the above drug products are solutions "intended for aerosolization", and "are considered to be pharmaceutically and therapeutically equivalent and are coded AN."
4. Glaxo's Ventolin<sup>®</sup> product contains dosing and administration information for pediatric use. The instructions call for dilution of 0.25 mL of the 0.5% concentration diluted in sterile normal saline solution to a total volume of 3mL prior to administration. This results in a concentration of 0.0417%.
5. The proposed drug product will help assure correct dosage by eliminating the possible error of diluting 0.25 mL of the 0.5% concentration with 2.75 mL of sterile normal saline (please note that I understand that sterile normal saline is only available only in 3mL unit dose containers or other containers which are much larger.
6. FDA has acknowledged that additional pediatric information on albuterol may produce health benefits in the pediatric population, as discussed in Docket No. 98N-0056.
7. The proposed drug product would provide a reference listed drug for in the Orange Book for the purpose of serving as the reference standard for bioequivalence of generic products for the pediatric concentration of 0.0417%.

**C. Environmental Impact**

The Petitioner claims a categorical exclusion under 21 CFR §25.24


**D. Economic Impact**

Allowing the submission and filing of an ANDA for the pre-diluted, non-preserved 0.0417% formulation; the public will be afforded access to a lower priced, equivalent dosage, non-preserved product for pediatric use. Currently, the public is required to purchase both the 0.5% concentrated albuterol and sterile, normal saline to attain the proper dilution.

Further, it is in the public interest to permit access to a pediatric concentration of albuterol sulfate inhalation solution that is manufactured under aseptic conditions and does not need a preservative.

**E. Certification**

The undersigned certifies, that, to the best knowledge and belief of the undersigned, this Petition includes all information and views on which the Petition relies, and that it includes representative data and information known to the Petitioner which are unfavorable to the Petition.



---

David L. Rosen., R.Ph., J.D.  
McDermott, Will & Emery  
600 13th Street, N.W.  
Washington, D.C. 20005-3096  
(202) 756-8075  
(202) 756-8087 (fax)

NDC #####-####-30

**Albuterol Sulfate  
Inhalation Solution, 0.0417%\***

**Albuterol Sulfate  
Inhalation Solution, 0.0417%\***

**1.25 mg/3 mL\***

\*Potency expressed as albuterol.

**1.25 mg/3 mL\***

\*Potency expressed as albuterol.

**FOR ORAL INHALATION ONLY**

Equivalent to 0.25 mL Albuterol Sulfate 0.5%\* diluted to 3 mL with normal saline.

**Attention Pharmacist:** Detach "Patient's Instructions For Use" from package insert and dispense with solution.

**Protect from light. Store between 2° and 25°C (36° and 77°F).** Discard if solution becomes discolored. (Note: Albuterol Sulfate Inhalation Solution is a clear, colorless to light yellow solution.)

**Rx only**

30 x 3-mL Sterile Unit Dose Vials

**FOR ORAL INHALATION ONLY**

Equivalent to 0.25 mL Albuterol Sulfate 0.5%\* diluted to 3 mL with normal saline.

**Attention Pharmacist:** Detach "Patient's Instructions For Use" from package insert and dispense with solution.

**Protect from light. Store between 2° and 25°C (36° and 77°F).** Discard if solution becomes discolored. (Note: Albuterol Sulfate Inhalation Solution is a clear, colorless to light yellow solution.)

**Rx only**

30 x 3-mL Sterile Unit Dose Vials

Albuterol Sulfate  
Inhalation Solution 0.0417%\*  
1.25 mg/3 mL\*  
\*Potency expressed as albuterol.

**Albuterol Sulfate  
Inhalation Solution, 0.0417%\***

1.25 mg/3 mL\*

\*Potency expressed as albuterol.

Each mL contains albuterol sulfate, equivalent to 0.417 mg albuterol in an aqueous solution containing sodium chloride, and sulfuric acid to adjust pH between 3 and 5. Contains no preservatives.

Please consult your physician before use. Do not exceed recommended dosage.

Usual Dosage: See package insert.

**Protect from light. Store between 2° and 25°C (36° and 77°F).**  
Discard if solution becomes discolored. (Note: Albuterol Sulfate Inhalation Solution is a clear, colorless to light yellow solution.)

Manufactured by:

REV. 3-01-00

**Albuterol Sulfate  
Inhalation Solution, 0.0417%\***

1.25 mg/3 mL\*

\*Potency expressed as albuterol.

Bar Code Area

Draft Copy  
- Pouch -

Albuterol Sulfate Inhalation Solution, 0.0417%  
3 mL, 30 per pouch

REV: 3-01-00  
Change Note # 00006

Drawn By:

Reviewed By:

Approved By:

## Albuterol Sulfate Inhalation Solution, 0.0417%\*

**1.25 mg/3 mL\***

\*Potency expressed as albuterol

### FOR ORAL INHALATION ONLY

### FOR PEDIATRIC USE ONLY

Equivalent to 0.25 mL Albuterol Sulfate 0.5%\* diluted to 3 mL with normal saline.

Each mL contains albuterol sulfate, equivalent to 0.417 mg albuterol in an aqueous solution containing sodium chloride, and sulfuric acid to adjust pH between 3 and 5. Contains no preservatives.

**Attention Pharmacist:** Detach "Patient's Instructions For Use" from package insert and dispense with solution.

Please consult your physician before use. Do not exceed recommended dosage.

Usual Dosage: See package insert.

**Protect from light. Store between 2° and 25° C (36° and 77° F).**


Discard if solution becomes discolored. (Note: Albuterol Sulfate Inhalation Solution is a clear, colorless to light yellow solution.)

Rx only.

Manufactured By:

30 x 3-mL Sterile Unit Dose Vials

rev. 3-01-00



**Albuterol Sulfate Inhalation Solution, 0.0417%**  
**3 mL vial.**

**Percent Incidence of Adverse Reactions (continued)**

Reaction	Percent Incidence n=135
<b>Gastrointestinal</b>	
Nausea	4%
Dyspepsia	1%
<b>Ear, nose, and throat</b>	
Nasal congestion	1%
Pharyngitis	<1%
<b>Cardiovascular</b>	
Tachycardia	1%
Hypertension	1%
<b>Respiratory</b>	
Bronchospasm	8%
Cough	4%
Bronchitis	4%
Wheezing	1%

No clinically relevant laboratory abnormalities related to Albuterol Sulfate Inhalation Solution administration were determined in these studies.

Rare cases of supraventricular tachycardia, urticaria, angioedema, rash, bronchospasm, and oropharyngeal edema have been reported after the use of inhaled albuterol.

**OVERDOSAGE**

The expected symptoms with overdosage are those of excessive beta-adrenergic stimulation and/or occurrence or exaggeration of any of the symptoms listed under ADVERSE REACTIONS, e.g., seizures, angina, hypertension or hypotension, tachycardia with rates up to 200 beats per minute, arrhythmias, nervousness, headache, tremor, dry mouth, palpitation, nausea, dizziness, fatigue, malaise, and sleeplessness. Hypokalemia may also occur. In isolated cases in children 2 to 12 years of age, tachycardia with rates >200 beats/min has been observed.

As with all sympathomimetic medications, cardiac arrest and even death may be associated with abuse of Albuterol Sulfate Inhalation Solution. Treatment consists of discontinuation of Albuterol Sulfate Inhalation Solution together with appropriate symptomatic therapy. The judicious use of a cardioselective beta-receptor blocker may be considered, bearing in mind that such medication can produce bronchospasm. There is insufficient evidence to determine if dialysis is beneficial for overdosage of Albuterol Sulfate Inhalation Solution.

The oral median lethal dose of albuterol sulfate in mice is greater than 2000 mg/kg (approximately 810 times the maximum recommended daily inhalation dose for adults on a mg/m<sup>2</sup> basis, or, approximately 300 times the maximum recommended daily inhalation dose for children on a mg/m<sup>2</sup> basis). In mature rats, the subcutaneous (sc) median lethal dose of albuterol sulfate is approximately 450 mg/kg (approximately 365 times the maximum recommended daily inhalation dose for adults on a mg/m<sup>2</sup> basis, or, approximately 135 times the maximum recommended daily inhalation dose for children on a mg/m<sup>2</sup> basis). In small young rats, the sc median lethal dose is approximately 2000 mg/kg (approximately 1600 times the maximum recommended daily inhalation dose for adults on a mg/m<sup>2</sup> basis, or, approximately 600 times the maximum recommended daily inhalation dose for children on a mg/m<sup>2</sup> basis). The inhalational median lethal dose has not been determined in animals.

**DOSAGE AND ADMINISTRATION  
FOR PEDIATRIC USE ONLY**

**Children 2 to 12 Years of Age:** The usual dosage for children weighing between 10 kg (22 pounds) and 15 kg (33 pounds) is 1.25 mg of albuterol (one unit-of-use vial) administered three to four times daily by nebulization. More frequent administration or higher doses are not recommended. The flow rate is regulated to suit the particular nebulizer so that albuterol sulfate inhalation solution will be delivered over approximately 5 to 15 minutes.

The use of Albuterol Sulfate Inhalation Solution can be continued as medically indicated to control recurring bouts of bronchospasm. During this time most patients gain optimal benefit from regular use of the inhalation solution.

If a previously effective dosage regimen fails to provide the usual relief, medical advice should be sought immediately as this is often a sign of seriously worsening asthma that would require reassessment of therapy.

Drug compatibility (physical and chemical), efficacy, and safety of Albuterol Sulfate Inhalation Solution when mixed with other drugs in a nebulizer have not been established.

**HOW SUPPLIED**

Albuterol Sulfate Inhalation Solution, 0.0417% is contained in plastic sterile unit dose vials of 3 mL each, supplied in foil pouches:

NDC #####-####-03 carton of 30 vials

Protect from light. Store between 2° and 25° C (36° and 77° F). Discard if solution becomes discolored. (Note: Albuterol Sulfate Inhalation Solution is a clear, colorless to light yellow solution.)

rev. 3-01-00

**PHARMACIST: DETACH HERE AND GIVE INSTRUCTIONS TO PATIENT**

**PATIENT'S INSTRUCTIONS FOR USE (continued)**

The safety and effectiveness of Albuterol Sulfate Inhalation Solution have not been determined when one or more drugs are mixed with it in a nebulizer. Check with your doctor before mixing any medications in your nebulizer.

Protect from light. Store between 2° and 25° C (36° and 77° F). Discard if solution becomes discolored. (Note: Albuterol Sulfate Inhalation Solution is a clear, colorless to light yellow solution.)

ADDITIONAL INSTRUCTIONS: \_\_\_\_\_  
 \_\_\_\_\_  
 \_\_\_\_\_


rev. 3-01-00

**Albuterol Sulfate Inhalation Solution, 0.0417%\***

\*Potency expressed as albuterol.

**DESCRIPTION**

Albuterol Sulfate Inhalation Solution is a relatively selective beta<sub>2</sub>-adrenergic bronchodilator (see CLINICAL PHARMACOLOGY). Albuterol sulfate, USP, the racemic form of albuterol, has the chemical name α'-(*tert*-Butylamino)methyl-4-hydroxy-*m*-xylene-α,α'-diol sulfate (2:1) (salt) and the following structural formula:



Albuterol sulfate has a molecular weight of 576.71, and the molecular formula is (C<sub>13</sub>H<sub>21</sub>NO<sub>3</sub>)<sub>2</sub> • H<sub>2</sub>SO<sub>4</sub>. Albuterol sulfate is a white crystalline powder, soluble in water and slightly soluble in ethanol.

The World Health Organization recommended name for albuterol base is salbutamol. Albuterol Sulfate Inhalation Solution requires no dilution before administration by nebulization.

Each milliliter of Albuterol Sulfate Inhalation Solution contains 0.417 mg of albuterol (as 0.5 mg of albuterol sulfate) in an isotonic, sterile, aqueous solution containing sodium chloride; sulfuric acid is used to adjust the pH to between 3 and 5. Albuterol Sulfate Inhalation Solution contains no sulfiting agents or preservatives.

Albuterol Sulfate Inhalation Solution is a clear, colorless to light yellow solution.

**CLINICAL PHARMACOLOGY**

*In vitro* studies and *in vivo* pharmacologic studies have demonstrated that albuterol has a preferential effect on beta<sub>2</sub>-adrenergic receptors compared with isoproterenol. While it is recognized that beta<sub>2</sub>-adrenergic receptors are the predominant receptors in bronchial smooth muscle, data indicate that 10% to 50% of the beta-receptors in the human heart may be beta<sub>2</sub>-receptors. The precise function of these receptors has not been established.

The pharmacologic effects of beta-adrenergic agonist drugs, including albuterol, are at least in part attributable to stimulation through beta-adrenergic receptors of intracellular adenylyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cyclic AMP). Increased cyclic AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.

Albuterol has been shown in most controlled clinical trials to have more effect on the respiratory tract, in the form of bronchial smooth muscle relaxation, than isoproterenol at comparable doses while producing fewer cardiovascular effects.

Controlled clinical studies and other clinical experience have shown that inhaled albuterol, like other beta-adrenergic agonist drugs, can produce a significant cardiovascular effect in some patients, as measured by pulse rate, blood pressure, symptoms, and/or electrocardiographic changes.

Albuterol is longer acting than isoproterenol in most patients by any route of administration because it is not a substrate for the cellular uptake processes for catecholamines nor for catechol-O-methyl transferase.

**Pharmacokinetics:** Studies in asthmatic patients have shown that less than 20% of a single albuterol dose was absorbed following either IPPB (intermittent positive-pressure breathing) or nebulizer administration; the remaining amount was recovered from the nebulizer and apparatus and expired air. Most of the absorbed dose was recovered in the urine 24 hours after drug administration. Following a 3-mg dose of nebulized albuterol in adults, the maximum albuterol plasma levels at 0.5 hours were 2.1 ng/mL (range, 1.4 to 3.2 ng/mL). There was a significant dose-related response in FEV<sub>1</sub> (forced expiratory volume in one second) and peak flow rate. It has been demonstrated that following oral administration of 4 mg of albuterol, the elimination half-life was 5 to 6 hours.

**Preclinical:** Intravenous studies in rats with albuterol sulfate have demonstrated that albuterol crosses the blood-brain barrier and reaches brain concentrations amounting to approximately 5.0% of the plasma concentrations. In structures outside the brain barrier (pineal and pituitary glands), albuterol concentrations were found to be 100 times those in the whole brain.

Studies in laboratory animals (minipigs, rodents, and dogs) have demonstrated the occurrence of cardiac arrhythmias and sudden death (with histologic evidence of myocardial necrosis) when beta-agonists and methylxanthines were administered concurrently. The clinical significance of these findings is unknown.

**Clinical Trials:** In controlled clinical trials in adults, most patients exhibited an onset of improvement in pulmonary function within 5 minutes as determined by FEV<sub>1</sub>. FEV<sub>1</sub> measurements also showed that the maximum average improvement in pulmonary function usually occurred at approximately 1 hour following inhalation of 2.5 mg of albuterol by compressor-nebulizer and remained close to peak for 2 hours. Clinically significant improvement in pulmonary function (defined as maintenance of a 15% or more increase in FEV<sub>1</sub> over baseline values) continued for 3 to 4 hours in most patients, with some patients continuing up to 6 hours.

Published reports of trials in asthmatic children aged 3 years or older have demonstrated significant improvement in either FEV<sub>1</sub> or PEF within 2 to 20 minutes following single doses of albuterol inhalation solution. An increase of 15% or more in baseline FEV<sub>1</sub> has been observed in children aged 5 to 11 years up to 6 hours after treatment with doses of 0.10 mg/kg or higher of albuterol inhalation solution. Single doses of 3, 4, or 10 mg resulted in improvement in baseline PEF that was comparable in extent and duration to a 2-mg dose, but doses above 3 mg were associated with heart rate increases of more than 10%.

**INDICATIONS AND USAGE**

Albuterol Sulfate Inhalation Solution is indicated for the relief of bronchospasm in patients 2 years of age and older with reversible obstructive airway disease and acute attacks of bronchospasm.

**PHARMACIST: DETACH HERE AND GIVE INSTRUCTIONS TO PATIENT**

**Albuterol Sulfate Inhalation Solution, 0.0417%\***

1.125 mg/3 mL\*

\*Potency expressed as albuterol

**PATIENT'S INSTRUCTIONS FOR USE FOR PEDIATRIC USE ONLY**

Read complete instructions carefully before using.

1. Twist open the top of one Albuterol Sulfate Inhalation Solution unit-of-use container and squeeze the entire contents into the nebulizer reservoir (Figure 1).



Figure 1

## CONTRAINDICATIONS

Albuterol Sulfate Inhalation Solution is contraindicated in patients with a history of hypersensitivity to albuterol or any of its components.

## WARNINGS

**Paradoxical Bronchospasm:** Albuterol Sulfate Inhalation Solution can produce paradoxical bronchospasm, which may be life threatening. If paradoxical bronchospasm occurs, Albuterol Sulfate Inhalation Solution should be discontinued immediately and alternative therapy instituted. It should be recognized that paradoxical bronchospasm, when associated with inhaled formulations, frequently occurs with the first use of a new canister or vial.

**Cardiovascular Effects:** Albuterol Sulfate Inhalation Solution, like all other beta-adrenergic agonists, can produce a clinically significant cardiovascular effect in some patients as measured by pulse rate, blood pressure, and/or symptoms. Although such effects are uncommon after administration of Albuterol Sulfate Inhalation Solution at recommended doses, if they occur, the drug may need to be discontinued. In addition, beta-agonists have been reported to produce electrocardiogram (ECG) changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The clinical significance of these findings is unknown. Therefore, Albuterol Sulfate Inhalation Solution, like all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension.

**Deterioration of Asthma:** Asthma may deteriorate acutely over a period of hours or chronically over several days or longer. If the patient needs more doses of Albuterol Sulfate Inhalation Solution than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids.

**Immediate Hypersensitivity Reactions:** Immediate hypersensitivity reactions may occur after administration of albuterol, as demonstrated by rare cases of urticaria, angioedema, rash, bronchospasm, and oropharyngeal edema.

**Use of Anti-Inflammatory Agents:** The use of beta-adrenergic agonist bronchodilators alone may not be adequate to control asthma in many patients. Early consideration should be given to adding anti-inflammatory agents, e.g., corticosteroids.

## PRECAUTIONS

**General:** Albuterol, as with all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension; in patients with convulsive disorders, hyperthyroidism, or diabetes mellitus; and in patients who are unusually responsive to sympathomimetic amines. Clinically significant changes in systolic and diastolic blood pressure have been seen in individual patients and could be expected to occur in some patients after use of any beta-adrenergic bronchodilator.

Large doses of intravenous albuterol have been reported to aggravate pre-existing diabetes mellitus and ketoacidosis. As with other beta-agonists, albuterol may produce significant hypokalemia in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects. The decrease is usually transient, not requiring supplementation.

Repeated dosing with 0.15 mg/kg of albuterol inhalation solution in children aged 5 to 17 years who were initially normokalemic has been associated with an asymptomatic decline of 20% to 25% in serum potassium levels.

**Information For Patients:** The action of Albuterol Sulfate Inhalation Solution may last up to 6 hours or longer. Albuterol Sulfate Inhalation Solution should not be used more frequently than recommended. Do not increase the dose or frequency of Albuterol Sulfate Inhalation Solution without consulting your physician. If you find that treatment with Albuterol Sulfate Inhalation Solution becomes less effective for symptomatic relief, your symptoms become worse, and/or you need to use the product more frequently than usual, you should seek medical attention immediately. While you are using Albuterol Sulfate Inhalation Solution, other inhaled drugs and asthma medications should be taken only as directed by your physician. Common adverse effects include palpitations, chest pain, rapid heart rate, and tremor or nervousness. If you are pregnant or nursing, contact your physician about use of Albuterol Sulfate Inhalation Solution. Effective and safe use of Albuterol Sulfate Inhalation Solution includes an understanding of the way that it should be administered.

Drug compatibility (physical and chemical), efficacy, and safety of Albuterol Sulfate Inhalation Solution when mixed with other drugs in a nebulizer have not been established. See illustrated Patient's Instructions for Use.

**Drug Interactions:** Other short-acting sympathomimetic aerosol bronchodilators or epinephrine should not be used concomitantly with albuterol. If additional adrenergic drugs are to be administered by any route, they should be used with caution to avoid deleterious cardiovascular effects.

**Monoamine Oxidase Inhibitors or Tricyclic Antidepressants:** Albuterol should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, because the action of albuterol on the vascular system may be potentiated.

**Beta-Blockers:** Beta-adrenergic receptor blocking agents not only block the pulmonary effect of beta-agonists, such as Albuterol Sulfate Inhalation Solution, but may produce severe bronchospasm in asthmatic patients. Therefore, patients with asthma should not normally be treated with beta-blockers. However, under certain circumstances, e.g., as prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of beta-adrenergic blocking agents in patients with asthma. In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution.

**Diuretics:** The ECG changes and/or hypokalemia that may result from the administration of nonpotassium-sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is not known, caution is advised in the coadministration of beta-agonists with nonpotassium-sparing diuretics.

**Digoxin:** Mean decreases of 16% to 22% in serum digoxin levels were demonstrated after single-dose intravenous and oral administration of albuterol, respectively, to normal volunteers who had received digoxin for 10 days. The clinical significance of these findings for patients with obstructive airway disease who are receiving albuterol and digoxin on a chronic basis is unclear. Nevertheless, it would be prudent to carefully evaluate the serum digoxin levels in patients who are currently receiving digoxin and albuterol.

**Carcinogenesis, Mutagenesis, Impairment of Fertility:** In a 2-year study in Sprague-Dawley rats, albuterol sulfate caused a significant dose-related increase in the incidence of benign leiomyomas of the mesovarium at dietary doses of 2.0, 10, and 50 mg/kg (approximately 2, 8, and 40 times, respectively, the maximum recommended daily inhalation dose for adults on a mg/m<sup>2</sup> basis, or, approximately 3/5, 3, and 15 times, respectively, the maximum recommended daily inhalation dose in children on a mg/m<sup>2</sup> basis). In another study this effect was blocked by the coadministration of propranolol, a non-selective beta-adrenergic antagonist. In an 18-month study in CD-1 mice albuterol sulfate showed no evidence of tumorigenicity at dietary doses of up to 500 mg/kg (approximately 200 times the maximum recommended daily inhalation dose for adults on a mg/m<sup>2</sup> basis, or, approximately 75 times the maximum recommended daily inhalation dose for children on a mg/m<sup>2</sup> basis). In a 22-month study in the Golden hamster albuterol sulfate showed no evidence of tumorigenicity at dietary doses of up to 50 mg/kg (approximately 25 times the maximum recommended daily inhalation dose for adults on a mg/m<sup>2</sup> basis, or, approximately 10 times the maximum recommended daily inhalation dose for children on a mg/m<sup>2</sup> basis). Albuterol sulfate was not mutagenic in the Ames test with or without metabolic activation using tester strains *S. typhimurium* TA1537, TA1538, and TA98 or *E. coli* WP2, WP2uvrA, and WP67. No forward mutation was seen in yeast strain *S. cerevisiae* S9 nor any mitotic gene conversion in yeast strain *S. cerevisiae* JD1 with or without metabolic activation. Fluctuation assays in *S. typhimurium* TA98 and *E. coli* WP2, both with metabolic activation, were negative. Albuterol sulfate was not clastogenic in a human peripheral lymphocyte assay or in an AH1 strain mouse micronucleus assay at intraperitoneal doses of up to 200 mg/kg.

Reproduction studies in rats demonstrated no evidence of impaired fertility at oral doses up to 50 mg/kg (approximately 40 times the maximum recommended daily inhalation dose for adults on a mg/m<sup>2</sup> basis).

**Pregnancy: Teratogenic Effects: Pregnancy Category C:** Albuterol has been shown to be teratogenic in mice. A study in CD-1 mice at subcutaneous (sc) doses of 0.025, 0.25, and 2.5 mg/kg (approximately 1/100, 1/10, and 1.0 times, respectively, the maximum recommended daily inhalation dose for adults on a mg/m<sup>2</sup> basis), showed cleft palate formation in 5 of 111 (4.5%) fetuses at 0.25 mg/kg and in 10 of 108 (9.3%) fetuses at 2.5 mg/kg. The drug did not induce cleft palate formation at the lowest dose, 0.025 mg/kg. Cleft palate also occurred in 22 of 72 (30.5%) fetuses from females treated with 2.5 mg/kg isoproterenol (positive control) subcutaneously, (approximately 1.0 times the maximum recommended daily inhalation dose for adults on a mg/m<sup>2</sup> basis).

A reproduction study in Stride Dutch rabbits revealed cranioschisis in 7 of 19 (37%) fetuses when albuterol was administered orally at a 50 mg/kg dose (approximately 80 times the maximum recommended daily inhalation dose for adults on a mg/m<sup>2</sup> basis).

There are no adequate and well-controlled studies in pregnant women. Albuterol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. During worldwide marketing experience, various congenital anomalies, including cleft palate and limb defects, have been rarely reported in the offspring of patients being treated with albuterol. Some of the mothers were taking multiple medications during their pregnancies. No consistent pattern of defects can be discerned, and a relationship between albuterol use and congenital anomalies has not been established.

**Use in Labor and Delivery:** Because of the potential for beta-agonist interference with uterine contractility, use of Albuterol Sulfate Inhalation Solution for relief of bronchospasm during labor should be restricted to those patients in whom the benefits clearly outweigh the risk.

**Tocolysis:** Albuterol has not been approved for the management of preterm labor. The benefit/risk ratio when albuterol is administered for tocolysis has not been established. Serious adverse reactions, including maternal pulmonary edema, have been reported during or following treatment of premature labor with beta<sub>2</sub>-agonists, including albuterol.

**Nursing Mothers:** It is not known whether this drug is excreted in human milk. Because of the potential for tumorigenicity shown for albuterol in some animal studies, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

**Pediatric Use:** The safety and effectiveness of Albuterol Sulfate Inhalation Solution have been established in children 2 years of age or older. Use of Albuterol Sulfate Inhalation Solution in these age-groups is supported by evidence from adequate and well-controlled studies of Albuterol Sulfate Inhalation Solution in adults; the likelihood that the disease course, pathophysiology, and the drug's effect in pediatric and adult patients are substantially similar; and published reports of trials in pediatric patients 3 years of age or older. The recommended dose for the pediatric population is based upon three published dose comparison studies of efficacy and safety in children 5 to 17 years, and on the safety profile in both adults and pediatric patients at doses equal to or higher than the recommended doses. The safety and effectiveness of Albuterol Sulfate Inhalation Solution in children below 2 years of age have not been established.

## ADVERSE REACTIONS

The results of clinical trials with Albuterol Sulfate Inhalation Solution, 0.5% in 135 patients showed the following side effects that were considered probably or possibly drug related:

### Percent Incidence of Adverse Reactions

Reaction	Percent Incidence n=135
<b>Central Nervous System</b>	
Tremors	20%
Dizziness	7%
Nervousness	4%
Headache	3%
Sleeplessness	1%

## PHARMACIST: DETACH HERE AND GIVE INSTRUCTIONS TO PATIENT

### PATIENT'S INSTRUCTIONS FOR USE (continued)

- Breathe as calmly, deeply and evenly as possible until no more mist is formed in the nebulizer chamber (about 5 to 15 minutes). At this point, the treatment is finished.
- Clean the nebulizer (see manufacturer's instructions).

**Note:** Use only as directed by your doctor. More frequent administration or higher doses are not recommended.

## PHARMACIST: DETACH HERE AND GIVE INSTRUCTIONS TO PATIENT

### PATIENT'S INSTRUCTIONS FOR USE (continued)

- Connect the nebulizer reservoir to the mouthpiece or face mask (Figure 2).



Figure 2

- Connect the nebulizer to the compressor.
- Sit in a comfortable, upright position; place the mouthpiece in your mouth (Figure 3)(or put on the face mask); and turn on the compressor.



Figure 3

OFFICE SERVICES  
MCDERMOTT, WILL & EMERY  
600 13TH ST N.W.  
WASHINGTON DC 20005  
(202)756-8010

SHIP DATE: 03MAR00  
ACC# 020045787

ACTUAL WGT: 1 LBS SCALE

TO: DOCKETS MGMT BRANCH  
FOOD & DRUG ADMINISTRATION DEPT  
5630 FISHERS LANE RM 1061  
OF HEALTH AND HUMAN SERVICE  
ROCKVILLE MD 20852

4113 6885 1624

FedEx

REF: 30076 010 1771

PRIORITY OVERNIGHT MON


CAD# 0011425 03MAR00

TRK# 4113 6885 1624 Form 0201

Deliver by:  
06MAR00

20852 -MD-US

IAD  
19 EDGA



World On-Time  
AIAA

# 153072077.SP G.T.F. 0199 ::